Table 2 Characteristics of patients and survival analysis (by the patterns of tumor enhancement)
Characteristic | Homogeneous enhancement (n = 82) | Heterogeneous enhancement (121) | Peripheral enhancement (52) | Statistics | P |
|---|---|---|---|---|---|
Age(years) | 51.35 ± 8.51 | 52.24 ± 10.37 | 52.00 ± 9.53 | 0.210 | 0.811 |
Menopause | Â | Â | Â | 1.388 | 0.499 |
Postmenopausal | 41 | 54 | 28 | Â | Â |
Premenopausal | 41 | 67 | 24 | Â | Â |
Family history | Â | Â | Â | 1.095 | 0.579 |
No | 76 | 111 | 50 | Â | Â |
Yes | 6 | 10 | 2 | Â | Â |
Diameter | 2.08 ± 0.91 | 2.31 ± 1.04 | 2.78 ± 1.28 | 7.028 | 0.001 |
Quadrant | Â | Â | Â | 12.629 | 0.125 |
Areolar | 2 | 1 | 2 | Â | Â |
Inner upper | 13 | 29 | 3 | Â | Â |
Inner lower | 11 | 9 | 5 | Â | Â |
Outer lower | 13 | 22 | 8 | Â | Â |
Outer upper | 43 | 60 | 34 | Â | Â |
Difference of MVD (Edge - Center) | -0.42 ± 5.72 | 3.73 ± 4.67 | 17.02 ± 3.88 | 211.273 | 0.000 |
Grade of DMVD | Â | Â | Â | 179.854 | 0.000 |
Uniform distribution | 77(93.9%) | 110(90.9%) | 0(0%) | Â | Â |
Uneven distribution | 5(6.1%) | 11(9.1%) | 52(100%) | Â | Â |
Histological grade | Â | Â | Â | 2.021 | 0.732 |
I | 22 | 31 | 10 | Â | Â |
II | 51 | 80 | 35 | Â | Â |
III | 9 | 10 | 7 | Â | Â |
Cancer thrombosis | Â | Â | Â | 2.910 | 0.233 |
Negative | 60 | 92 | 33 | Â | Â |
Positive | 22 | 29 | 19 | Â | Â |
Nodal metastasis | Â | Â | Â | 1.588 | 0.452 |
Negative | 25 | 61 | 22 | Â | Â |
Positive | 47 | 60 | 30 | Â | Â |
Number of metastatic nodes | 3.80 ± 6.88 | 2.51 ± 5.30 | 6.73 ± 10.17 | 6.540 | 0.002 |
Clinical stage | Â | Â | Â | 19.007 | 0.040 |
I | 20(24.4%) | 32(26.4%) | 7(13.5%) | Â | Â |
IIA | 25(30.5%) | 37(30.6%) | 14(26.9%) | Â | Â |
IIB | 29(35.4%) | 38(31.4%) | 17(32.7%) | Â | Â |
IIIA | 4(4.9%) | 10(8.3%) | 4(7.7%) | Â | Â |
IIIB | 2(2.4%) | 2(1.7%) | 3(5.8%) | Â | Â |
IIIC | 2(2.4%) | 2(1.7%) | 7(13.5%) | Â | Â |
IV | 0(0%) | 0(0%) | 0(0%) | Â | Â |
ER | Â | Â | Â | 31.203 | 0.000 |
Negative | 29(35.4%) | 32(26.4%) | 37(71.2%) | Â | Â |
Positive | 53(64.6%) | 89(73.6%) | 15(28.8%) | Â | Â |
PgR | Â | Â | Â | 34.485 | 0.000 |
Negative | 24(29.3%) | 29(24.0%) | 36(69.2%) | Â | Â |
Positive | 58(70.7%) | 92(76.0%) | 16(30.8%) | Â | Â |
HER2 | Â | Â | Â | 11.200 | 0.004 |
Negative | 70(85.4%) | 110(90.9%) | 37(71.2%) | Â | Â |
Positive | 12(14.6%) | 11(9.1%) | 15(28.8%) | Â | Â |
Ki67 | Â | Â | Â | 14.736 | 0.001 |
Negative (<14%= | 53(64.6%) | 77(63.6%) | 18(34.6%) | Â | Â |
Positive (>14%) | 29(35.4%) | 44(36.4%) | 34(65.4%) | Â | Â |
P53 (%) | 33.98 ± 32.59 | 30.35 ± 31.32 | 30.27 ± 33.83 | 0.357 | 0.700 |
Clinicopathological subtypes | Â | Â | Â | 59.901 | 0.000 |
Luminal A | 40(48.8%) | 71(58.7%) | 8(15.4%) | Â | Â |
Luminal B (Ki67+) | 18(22.0%) | 29(24.0%) | 5(9.6%) | Â | Â |
Luminal B (HER2+) | 7(8.5%) | 8(6.6%) | 7(13.5%) | Â | Â |
HER2 overexpression | 5(6.1%) | 3(2.5%) | 8(15.4%) | Â | Â |
TNBC | 12(14.6%) | 10(8.3%) | 24(46.2%) | Â | Â |
Operation | Â | Â | Â | 4.885 | 0.087 |
Mastectomy | 72 | 106 | 51 | Â | Â |
Tumorectomy | 10 | 15 | 1 | Â | Â |
Chemotherapy program | Â | Â | Â | 14.344 | 0.279 |
Not performed | 0 | 1 | 1 | Â | Â |
CMF | 1 | 1 | 0 | Â | Â |
CAF or AC | 23 | 42 | 7 | Â | Â |
CEF or EC | 19 | 27 | 16 | Â | Â |
T or TC or TP | 27 | 34 | 15 | Â | Â |
TAC or A-T | 12 | 16 | 13 | Â | Â |
Radiotherapy | Â | Â | Â | 1.560 | 0.458 |
Not performed | 40 | 69 | 26 | Â | Â |
Performed | 42 | 52 | 26 | Â | Â |
Endocrine therapy | Â | Â | Â | 53.381 | 0.000 |
Not performed | 17(20.7%) | 13(10.7%) | 32(61.5%) | Â | Â |
TAM | 38(46.3%) | 68(56.2%) | 13(25.0%) | Â | Â |
LHRH | 7(8.5%) | 8(6.6%) | 3(5.8%) | Â | Â |
AI | 20(24.4%) | 32(26.4%) | 4(7.7%) | Â | Â |
Targeted therapy | Â | Â | Â | 2.329 | 0.312 |
Not performed | 79 | 119 | 52 | Â | Â |
Performed | 3 | 2 | 0 | Â | Â |
Overall survival | 100% | 95.9% | 88.5% | 11.876 | 0.018 |
Event | 0 | 5 | 6 | Â | Â |
Deaths | 0 | 5 | 5 | Â | Â |
Lost to follow-up | 0 | 0 | 1 | Â | Â |
Median survival time | 54.0 | 54.0 | 42.0 | 8.525 | 0.014 |
Disease-free survival | 100% | 95.9% | 65.4% | 63.908 | 0.000 |
Event | 0 | 5 | 18 | Â | Â |
Local recurrence | 0 | 0 | 1 | Â | Â |
Contralateral breast cancer | 0 | 0 | 4 | Â | Â |
Lung metastasis | 0 | 0 | 2 | Â | Â |
Hepatic metastasis | 0 | 0 | 5 | Â | Â |
Brain metastasis | 0 | 1 | 2 | Â | Â |
Multi-organ | 0 | 4 | 3 | Â | Â |
Lost to follow-up | 0 | 0 | 1 | Â | Â |
Disease-free survival | 54.0 | 54.0 | 29.5 | 45.952 | 0.000 |
Follow-up time | Â | Â | Â | 2.967 | 0.053 |
Median | 21.0 | 25.0 | 21.0 | Â | Â |
Range | 12-56 | 12-59 | 12-44 | Â | Â |